A) Relative abundance of non-naïve CD8+ T cell
clusters in uiLN (T cell zone, n = 20) from anti-PD-L1 treated patients (n = 9).
Sample ID represents patient ID followed by LN number. B)
Non-naïve CD8+ T cell cluster ratios represented as log2 fold changes
between uiLN (T cell zone, n = 20) from anti-PD-L1 treated patients and uiLN (T
cell zone, n = 22) from SOC treated patients. C) Cluster 18 and 16
abundances (as percentage of non-naïve CD8+ T cells) in the T cell zone
of uiLN from SOC and anti-PD-L1 treated patients. D) Cluster
18/cluster 16 ratio in uiLN (T cell zone) from SOC and anti-PD-L1 treated
patients. E) Percentage of cluster 18 and 16 proliferating cells in
uiLN (T cell zone) from SOC and anti-PD-L1 treated patients. F-G)
Percentage of (F) cluster 18 and (G) cluster 16 cells
with a specific cell type as its neighbor in uiLN (T cell zone) from anti-PD-L1
treated patients. H) Number of DC neighbors for cluster 18 and
cluster 16 cells in uiLN (T cell zone) from SOC and anti-PD-L1 treated patients.
I) Number of cluster 16 neighbors for cluster 18 cells in uiLN
(T cell zone) from SOC and anti-PD-L1 treated patients. J-K) Number
of (J) PD-1 positive and (K) Ki-67+ neighbors for
cluster 18 and cluster 16 cells in uiLN (T cell zone) from SOC and anti-PD-L1
treated patients. L) Expression of PD-1 on cluster 18 and cluster
16 cells with a DC neighbor in uiLN (T cell zone) from SOC and anti-PD-L1
treated patients. M) Representative image of an uiLN from an
anti-PD-L1 treated patient (patient 01) showing the spatial localization of CD4
T cells, Tregs, DCs, Tpex (cluster 18), and Tex-int (cluster 16). Cell identity
overlaid onto the segmentation mask. Highlighted region is colored by the
expression of CD8+ (red), PD-1 (green), TCF-1 (cyan), CD11c (purple), Ki-67
(yellow), CD4 (cyan), and FoxP3 (purple). C-E and H-L)
P-values obtained by Wilcoxon Rank Sum Test. See also Figure S4.